Featured Professionals: Cheairs Porter, Dan Linsalata, Rob Crampton

The pharma commercialization services sector is benefiting from a powerful set of structural tailwinds—including a replenished drug development pipeline, growing complexity of novel modalities, and greater adoption of AI-driven commercialization tools—all of which are creating robust and sustained demand for third-party commercialization expertise.

Below, our Healthcare & Life Sciences Group shares what our recent client The Deerfield Group reveals about the segment’s investment potential.

An Influx of Complex Drug Launches

Global drug sales are projected to expand at an estimated 7% CAGR due to the proliferation of GLP-1s, advancements in personalized medicine, and a broad-based supportive backdrop of pharma R&D spend that’s expected to rise beyond pre-pandemic levels.

“Supported by pharma’s recovery and an influx of upcoming drug launches, we expect demand for outsourced marketing, media, and communications services to see sustained growth,” says Cheairs Porter, a managing director.

And across this growing drug development pipeline, products are becoming more specialized, complicated, and expensive than ever—driving complex marketing challenges and further bolstering the need for commercialization businesses. “To combat an increase in chronic and rare diseases, drug development continues to see ongoing innovation, favoring targeted and personalized treatments that are more difficult to develop and costly to bring to market,” adds Porter. “This is creating a unique set of marketing obstacles that require dedicated expertise to navigate.”

Meanwhile, evolving technology is heightening the value that leading commercialization companies can bring to the table. For instance, harnessing emerging digital channels enables stronger healthcare professional and patient engagement, measuring campaign performance drives optimized strategies and focused spending, and adopting generative AI tools boosts efficiency while helping pharma stretch budgets and maximize impact.

“The market’s growing use of digital channels and new technology to target and engage healthcare professionals is fueling greater digital marketing spending,” says Dan Linsalata, a managing director. “Deerfield and similar companies that make strategic investments in differentiated digital and media capabilities are well positioned to outpace market growth.”

Deerfield: Supporting All Stages of Development and Commercialization

The Deerfield Group is a fully integrated marketing, communications, and media partner providing innovative solutions for pharmaceutical, biotechnology, health tech, and consumer health companies. With services across each phase of drug development, Deerfield supports its customers pre-launch through brand maintenance while providing brand strategy throughout a drug’s commercial life. Harris Williams advised Deerfield, a portfolio company of The Edgewater Funds, on its strategic majority investment from Martis Capital.

A key to Deerfield’s growth is its specialist teams that combine deep medical and scientific knowledge with extensive marketing experience. “It’s very unique to have a group of professionals with therapeutic area expertise as well as experience across insights and strategy, creative and digital, omnichannel marketing, media, public relations, data and analytics, sales enablement, and print management,” says Porter.

These teams employ a data-driven approach enabled by technology and AI to maximize impact and enhance service delivery efficiency. “Deerfield’s technology-focused approach positions it as a leader in innovation, blending AI tools with sector expertise to deliver impactful solutions for clients while creating internal operating efficiencies,” says Linsalata.

In addition, Deerfield’s differentiated model leverages the right teams, processes, and solutions at the right time to drive agility—improving turnarounds, reducing delivery costs, and maintaining above-average margins at a competitive price point. “Deerfield has created a unique value proposition for its clients,” says Rob Crampton, a director. “The company puts seasoned experts in the room to work as an extension of a customer’s brand team, offers services on a fixed-fee basis to drive efficiency, and brings more value through a scalable delivery model.”

“From its inception, Deerfield has been focused on innovation, efficiency, and solving more client problems,” adds Porter. “Because of this, the company has seen great success and is poised for sustained growth through expansion within core markets, the addition of complementary capabilities, further technology adoption, and accretive M&A.”

Comprehensive Commercial Support

An expanding and more complicated drug development pipeline is driving complex marketing challenges and bolstering demand for outsourced commercialization services. At the same time, pharma and biotech companies are increasingly focused on personalized, data-driven engagement to better target healthcare professionals, boosting the importance of marketing expertise.

“Rising pharma revenues and more drug launches will continue to drive spending on marketing, media, and communications,” says Porter. “Going forward, investors will keep seeking partners like Deerfield that can provide end-to-end commercial support, ranging from brand strategy and creative development through digital media execution.”

To further discuss outsourced pharma services M&A, please contact our senior professionals.